CN111234021B - 一种抗ccr5抗体及其在***中的应用 - Google Patents
一种抗ccr5抗体及其在***中的应用 Download PDFInfo
- Publication number
- CN111234021B CN111234021B CN202010131750.8A CN202010131750A CN111234021B CN 111234021 B CN111234021 B CN 111234021B CN 202010131750 A CN202010131750 A CN 202010131750A CN 111234021 B CN111234021 B CN 111234021B
- Authority
- CN
- China
- Prior art keywords
- antibody
- ccr
- ccr5
- melanoma
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
名称 | EC50(ng/ml) |
9D6 | 42.8±11.2 |
4E8 | 54.2±12.9 |
对照-抗体B | 94.3±24.7 |
名称 | IC50(μg/ml) |
9D6 | 6.3 |
4E8 | 12.1 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010131750.8A CN111234021B (zh) | 2020-02-29 | 2020-02-29 | 一种抗ccr5抗体及其在***中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010131750.8A CN111234021B (zh) | 2020-02-29 | 2020-02-29 | 一种抗ccr5抗体及其在***中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111234021A CN111234021A (zh) | 2020-06-05 |
CN111234021B true CN111234021B (zh) | 2020-09-08 |
Family
ID=70868115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010131750.8A Active CN111234021B (zh) | 2020-02-29 | 2020-02-29 | 一种抗ccr5抗体及其在***中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111234021B (zh) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014505239A (ja) * | 2010-12-14 | 2014-02-27 | モアハウス スクール オブ メディスン | 癌の治療または検出のための抗cxcl13および抗cxcr5抗体の使用 |
WO2017201043A1 (en) * | 2016-05-16 | 2017-11-23 | Concert Pharmaceuticals, Inc. | Combination therapy for treating cancer |
-
2020
- 2020-02-29 CN CN202010131750.8A patent/CN111234021B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN111234021A (zh) | 2020-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI708787B (zh) | Pd-1促效劑抗體及其用途 | |
US20220002408A1 (en) | Bispecific antibody, preparation method thereof and application thereof | |
JP6006404B2 (ja) | 抗BLyS抗体 | |
CN110914304A (zh) | Cd96抗体、其抗原结合片段及医药用途 | |
CN108026178A (zh) | 一种C5aR抗体及其制备方法和应用 | |
TWI701260B (zh) | 抗pacap抗體 | |
CN110546165B (zh) | 抗-pd-l1-抗-tim-3双特异性抗体 | |
EP3101035B1 (en) | Bifunctional fusion protein, preparation method therefor, and use thereof | |
CN111234021B (zh) | 一种抗ccr5抗体及其在***中的应用 | |
CN110922483B (zh) | 抗ccr5抗体及其在***中的应用 | |
CN111205370B (zh) | 抗ptn抗体在抑制白血病干细胞以及治疗慢性粒细胞白血病中的应用 | |
KR102598319B1 (ko) | 항-il-25 항체 및 그의 용도 | |
JP2021003111A (ja) | 抗−ヒトil−3抗体、il−3の高められた発現又はレベルに関連する疾患又は機能障害へのそれらの使用、及びヒトil−3の検出方法へのそれらの使用 | |
CN107074976B (zh) | 同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白 | |
CN114456267B (zh) | 一种抗cd73人源化单克隆抗体及其应用 | |
CN113698484B (zh) | 抗il-23r抗体及其用途 | |
US20230391879A1 (en) | Caninized antibodies to canine interleukin-31 receptor alpha | |
CA3239307A1 (en) | Caninized antibodies to canine interleukin-31 receptor alpha 1 | |
CA3239826A1 (en) | Caninized antibodies to canine interleukin-31 receptor alpha ii | |
CN113817058A (zh) | 一种抗人il-17rc的单克隆抗体及其应用 | |
WO2023111148A1 (en) | Caninized antibodies to canine interleukin-31 receptor alpha 1 | |
CN116724050A (zh) | 抗胸腺基质淋巴细胞生成素(tslp)抗体及其用途 | |
CN116133684A (zh) | 抗人nr1抗体衍生物 | |
CN116472287A (zh) | 犬白介素-31受体α的犬源化抗体 | |
CN116848144A (zh) | 抗pd-l1抗体及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200813 Address after: Area B, 6 / F, warehouse 2, Baisha logistics company, 3011 Shahe street, Nanshan District, Shenzhen City, Guangdong Province Applicant after: Shenzhen Zhongkang Lianda Health Biotechnology Co.,Ltd. Address before: No. 4315, 4th Floor, Building 7, Fengxian Middle Road, Haidian District, Beijing, 100000 Applicant before: BEIJING YUEHAO TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220525 Address after: 102200 floor 2-104, building 5, fengshujiayuan District 4, Changping District, Beijing Patentee after: Beijing Nuosai Life Medical Technology Co.,Ltd. Address before: 518000 zone B, 6 / F, warehouse 2 of Baisha logistics company, 3011 Shahe street, Nanshan District, Shenzhen, Guangdong Province Patentee before: Shenzhen Zhongkang Lianda Health Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220802 Address after: 319, floor 1, building 32, No. 119, Majia building, Huangtu Gang, Fengtai District, Beijing 100071 Patentee after: Beijing Nuosai International Medical Research Institute Address before: 102200 floor 2-104, building 5, fengshujiayuan District 4, Changping District, Beijing Patentee before: Beijing Nuosai Life Medical Technology Co.,Ltd. |